In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway
Molecules · 2023
DOI: 10.3390/molecules28031137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Michael A Fawzy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University Researchers, Princess Nourah bint Abdulrahman University, Princess Nourah bint Abdulrahman University Researchers Supporting Project.
Abstract (Originalsprache)
Novel drugs are desperately needed in order to combat a significant challenge due to chemo-therapeutic resistance and bad prognosis. This research aimed to assess the anticancer activity of a newly synthesized ciprofloxacin Mannich base (CMB) on ovarian cancer (OVCAR-3) and lung cancer (A-549) cell lines and to investigate probable involved molecular mechanisms. The cytotoxic and pro-apoptotic impact of CMB on both cell lines was investigated using MTT assay, Annexin V assay, and cell cycle analysis, as well as caspase-3 activation. Western blotting was carried out to evaluate downstream targets of the MAPK pathway, while qRT PCR was used to evaluate the gene expression pattern of the p53/Bax/Bcl2 pathway. CMB treatment showed significantly reduced cell proliferation in both OVCAR-3 and A-549 cells with half maximum inhibitory concentration (IC50) = 11.60 and 16.22 µg/mL, respectively. CMB also induced apoptosis, S phase cell cycle arrest, and up-regulated expression of p53, p21, and Bax while down-regulated Bcl2 expression. CMB also halted cell proliferation by deactivating the MAPK pathway. In conclusion, CMB may be regarded as a potential antiproliferative agent for lung and ovarian cancers due to anti-proliferative and pro-apoptotic actions via inhibition of the MAPK pathway and p53/Bax/Bcl2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, New-Minia, Minia 61511, Egypt, Egypt.
- Basic Health Sciences Department, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
ORCID-Profile: Michael A Fawzy, Rania H Abu-Baih, Islam M Abdel-Rahman, Azza A K El-Sheikh, Maiiada H Nazmy
Förderung
- Princess Nourah bint Abdulrahman University Researchers
- Princess Nourah bint Abdulrahman University
- Princess Nourah bint Abdulrahman University Researchers Supporting Project
Zitieren
APA
Fawzy, M. A., Abu-Baih, R. H., Abuo-Rahma, G. E. A., Abdel-Rahman, I. M., El-Sheikh, A. A. K., & Nazmy, M. H. (2023). In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway. Molecules. https://doi.org/10.3390/molecules28031137
Vancouver
Fawzy MA, Abu-Baih RH, Abuo-Rahma GEA, Abdel-Rahman IM, El-Sheikh AAK, Nazmy MH. In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway. Molecules. 2023. doi:10.3390/molecules28031137
BibTeX
@article{Fawzy2023,
author = {Fawzy, Michael A and Abu-Baih, Rania H and Abuo-Rahma, Gamal El-Din A and Abdel-Rahman, Islam M and El-Sheikh, Azza A K and Nazmy, Maiiada H},
title = {In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28031137}
}
EUVIMED